Integrative Therapies

As conversations on how to support veteran mental health evolve, there is growing interest in therapeutic approaches that extend into the integrative and holistic models of care. Integrative therapies—including mind-body practices, trauma-informed modalities, and plant-based treatments—are being explored in both clinical and supportive settings as potential tools for addressing PTSD, depression, and suicide risk.
Many of these therapies are not new, but are rooted in longstanding Indigenous and traditional practices that have supported healing for generations. Today, they are gaining increased recognition within Western research and can exist alongside mainstream approaches to mental health.
The Siotha Project is committed to staying updated on research and accessible resources in the evolving mental health landscape. While we do not provide or facilitate psychedelic-assisted therapies, we aim to serve as a trusted, grounded resource—helping veterans, families, and communities navigate information with clarity and care.
FEATURED CONTENT
​
The Siotha Project Blog Posts
​
​
Documentaries
​
-
In Waves and War – Follows veterans exploring alternative therapies, including ibogaine and 5-MeO-DMT, in clinical settings abroad.
​
Research & Organizations
​
-
MAPS (Multidisciplinary Association for Psychedelic Studies)
Research on MDMA-assisted therapy for PTSD
https://maps.org -
Johns Hopkins Center for Psychedelic & Consciousness Research
Ongoing studies on psilocybin and mental health
https://hopkinspsychedelic.org -
NYU Langone Center for Psychedelic Medicine
Clinical research on psychedelic-assisted therapies
https://med.nyu.edu/psychiatry/research/psychedelic-medicine -
U.S. Department of Veterans Affairs (VA) – Whole Health Program
Integrative approaches including mindfulness, movement, and wellness practices
https://www.va.gov/wholehealth/
Updates & Insights
​
-
March 2026 – Oregon and Colorado continue to implement regulated psilocybin programs, allowing supervised use in licensed settings.
-
March 2026 – MDMA-assisted therapy for PTSD remains under FDA review, with potential for future approval as a prescribable treatment.
-
Early 2026 – Expanded clinical trials across institutions like Johns Hopkins and NYU continue to study psilocybin’s impact on depression, trauma, and addiction.
-
Ongoing – Increased national attention on veteran-specific programs exploring alternative therapies, particularly for treatment-resistant PTSD and suicide prevention.
Regional Update (2026):
Texas continues to lead in veteran-focused research initiatives, while Oklahoma and New Mexico are in earlier stages of exploration, with growing interest in expanding access to emerging therapies through research and future policy development.